statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BCLI Update - Progress Supports Our 10x Plus Value Range Potential

BCLI Update - Progress Supports Our 10x Plus Value Range Potential BCLI Update - Progress Supports Our 10x Plus Value Range Potential PR Newswire LONDON, July 24, 2024 ACF Equity Research FROM ACF...

BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program PR Newswire NEW YORK, July 1...

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering PR Newswire NEW...

BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn Clinical Trial

BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn Clinical Trial BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn...

BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating...

BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn Clinical Effectiveness Expectation

BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn Clinical Effectiveness Expectation BCLI: Initiation - Potential 10x...

BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn

BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn BrainStorm Cell Therapeutics to Present New Biomarker Data...

BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides...

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn BrainStorm Cell Therapeutics Announces Management Changes as Company Plans...

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule PR Newswire NEW YORK, April...

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.

Volume	141,860.00
52-Wk High	$1.90
52-Wk Low	$0.134

BCLI Brainstorm Cell Therapeutics, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals